WIN 2016 Symposium in Parijs: “Innovatieve aanpak kan overlevingskans kankerpatiënt verbeteren”

VILLEJUIF, France–(BUSINESS WIRE)– WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8 ^th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration.
This year WIN has chosen to address the critical question facing cancer research:
How innovative use of targeted therapies can improve survival of greater numbers of cancer patients?

Under the chairmanship of Dr. Josep Tabernero, (Vall d’ Hebron, Spain), the WIN Symposium will present a unique opportunity by bringing together a forum of world-class experts from different backgrounds including patient advocacies, academic and private research institutes and industry to address contemporary challenges and controversies around the next innovative steps in cancer therapy that will significantly improve patients’ outcomes.

Themes that will be addressed:

• Patients’ and advocacy perspectives
• New tools for early diagnosis, selecting therapies and monitoring
• Innovative clinical trials to substantially improve outcome
• Relevant models and critical preclinical data before moving to the clinic
• Translation of big data into clinical opportunities

“ The annual symposium is the most visible part of the WIN Consortium’s activities, but perhaps the most exciting part of WIN is the engagement of all the different parties, from academic institutions to industry collaborators, and the unique opportunity this offers to truly collaborate in developing the next generation of clinical trials” John Mendelsohn, Chairman WIN Consortium, Director Khalifa Institute for Personalized Cancer Therapy, Past President, UT MDAnderson Cancer Center, USA.